Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026)
Entera Bio (ENTX) recorded quarterly Total Non-Current Liabilities of $866000.0 in Q1 2026, up 25.69% on a QoQ basis from $689000.0 in Q4 2025, and up 44.82% year-over-year from $598000.0 in Q1 2025.
Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Entera Bio has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $866000.0 for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 44.82% year-over-year to $866000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866000.0 (up 44.82% YoY) and the FY2025 annual result came in at $689000.0, up 414.18% from the prior year.
- Total Non-Current Liabilities improved to $866000.0 in Q1 2026, from $689000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $866000.0 in Q1 2026 and troughed at $32000.0 in Q4 2022.
- A 5-year average of $323235.3 and a median of $255000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 87.74% — and 2023, when it surged 800.0%.
- Tracing ENTX's Total Non-Current Liabilities over 5 years: stood at $32000.0 in 2022, then jumped by 800.0% to $288000.0 in 2023, then sank by 53.47% to $134000.0 in 2024, then jumped by 414.18% to $689000.0 in 2025, then advanced by 25.69% to $866000.0 in 2026.
- Business Quant data shows ENTX's Total Non-Current Liabilities at $866000.0 in Q1 2026, $689000.0 in Q4 2025, and $602000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 866,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 866,000.00 |
| Dec 31, 2025 | 689,000.00 |
| Sep 30, 2025 | 602,000.00 |
| Jun 30, 2025 | 567,000.00 |
| Mar 31, 2025 | 598,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 348,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 35,000.00 |
| Jun 30, 2022 | 127,000.00 |
| Mar 31, 2022 | 233,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Dec 31, 2020 | 371,000.00 |
| Dec 31, 2018 | 1.44 Mn |